Brokerage Firm Rating on Insulet Corporation (PODD)

Insulet Corporation (PODD) : 16 analysts are covering Insulet Corporation (PODD) and their average rating on the stock is 1.94, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Insulet Corporation (PODD) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 7 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Insulet Corporation (PODD) stock is expected to deviate a maximum of $4 from the average target price of $41.84 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $50 and the most muted being $38.


For the current week, the company shares have a recommendation consensus of Buy. Insulet Corporation (NASDAQ:PODD): The stock opened at $43.88 on Thursday but the bulls could not build on the opening and the stock topped out at $43.97 for the day. The stock traded down to $42.84 during the day, due to lack of any buying support eventually closed down at $42.86 with a loss of -2.26% for the day. The stock had closed at $43.85 on the previous day. The total traded volume was 509,185 shares.

In a related news, Sommer Regina O, director of Insulet Corp, unloaded 8,019 shares at an average price of $30.42 on May 25, 2016. The total amount of the transaction was worth $243,938, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.